Cefepime monotherapy was compared with cefepime-plus-amikacin dual therapy for treatment of febrile neutropenic patients. Response rates were significantly lower for patients receiving monotherapy who had neutrophil counts of !500 cells/mm 3 but did not differ significantly between patients receiving dual therapy who had neutrophil counts of у500 cells/mm 3 or !500 cells/mm 3 . Dual therapy is recommended for the initial treatment of patients with neutropenia with !500 cells/mm 3 . Dual therapy was significantly more effective in patients with neutropenia lasting !5 days. The response rates to monotherapy or dual therapy did not differ significantly when neutropenia persisted for у6 days, indicating that sustained neutropenia is a risk factor for failure of initial empirical therapy. The rate of response to monotherapy was lower in leukemic patients, whereas the rate of response to dual therapy did not differ between leukemic and nonleukemic groups. The rate of response to either monotherapy or dual therapy did not differ for patients with temperatures of у38ЊC or 37.5ЊC-38ЊC. Overall, defervescence occurred in 180% of patients with mild infections, whereas only 32% of those with moderate to severe infection responded by day 3 and 69.8% by day 7.
It is important to establish a set of criteria for the clinical management of febrile neutropenia in patients receiving myelosuppressive treatment who are to receive empirical antimicrobial therapy. Moreover, establishing the clinical severity of febrile neutropenia might be advantageous for the management of the infectious complications. The Infectious Diseases Society of America (IDSA) guidelines provide risk factors for severe infection in patients with neutropenia (tables 1 and 2) [1] . An important marker of low risk in these patients is a neutrophil count of у100 cells/mm 3 , without apparent complications.
CEFEPIME IN THE TREATMENT OF SEVERE INFECTIONS ACCOMPANYING HEMATOLOGIC DISEASES
In the study by Tamura et al. [2] , cefepime monotherapy was compared with dual therapy with cefepime and amikacin for febrile neutropenic patients, most
Reprints or correspondence: Dr. Kazuma Ohyashiki, Tokyo Medical University, 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan (ohyashik@rr.iil4u.or.jp). , and significance was placed on the duration of neutropenia [3] . Fever was defined as an axillary temperature of у37.5ЊC, which is in accordance with the prevailing clinical practice in Japan.
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NEUTROPHIL COUNT
The study of Tamura et al. [2] demonstrated that the neutrophil count should be considered before monotherapy or dual therapy is prescribed. Among febrile neutropenic patients initially treated with cefepime monotherapy, those with neutrophil counts of !500 cells/mm 3 had significantly lower response rates at day 3 compared with those with neutrophil counts of 500-1000 cells/mm 3 (27.6% vs. 52.6%; ). In contrast, P p .038 the rate of response to dual therapy did not differ significantly between patients with neutrophil counts of у500 cells/mm 3 and those with neutrophil counts of !500 cells/mm 3 (45% vs. 50%;
). Dual therapy was more effective than mono-P p .729 therapy for patients with severe neutropenia (45% vs. 27.6%;
). These findings confirm the importance of neutro-P p .024 phil counts at the time of antibiotic administration, before the selection of monotherapy versus dual therapy. Therefore, dual therapy should be given initially to febrile neutropenic patients with neutrophil counts of !500 cells/mm 3 , particularly to those with severe neutropenia-that is, counts of !100 cells/mm 3 -in accordance with the IDSA guidelines (table 1). Urabe et al. [3] reported a 61.8% response rate to cefepime with or without amikacin among patients with neutrophil counts of !100 cells/ mm 3 and a 66.1% response rate in those with neutrophil counts of 100-1000 cells/mm 3 . The difference between the study by Tamura et al. [2] and that by Urabe et al. [3] may be due to the difference in the duration of neutropenia in the patient population, as described below.
DURATION OF NEUTROPENIA
The duration of neutropenia is also an important determinant of response at day 7. In the study by Tamura et al. [2] , for patients with neutrophil counts of !100 cells/mm 3 whose neutropenia resolved !5 days after the administration of antibiotics, dual therapy with cefepime and amikacin was significantly more effective than monotherapy (88.1% vs. 70.9%; P p .022). Patients whose neutropenia persisted for у6 days who received either monotherapy or dual therapy did not show a significant difference in response rates (55.0% vs. 57.1%; P p .852). However, an aminoglycoside was added to the regimen at day 4 for patients who did not respond to the initial cefepime monotherapy. Growth factors were also administered on the basis of the judgment of individual physicians. Of note, only 55%-57% of patients with sustained severe neutropenia (!100 cells/mm 3 for у6 days) responded to either monotherapy or dual therapy. This clearly indicates that sustained severe neutropenia is a risk factor for failure of empirical antibiotic therapy, even with dual therapy. The above support the IDSA guidelines that a duration of neutropenia of !7 days indicates a low risk for severe infections (table 1) .
UNDERLYING DISEASE
The underlying disease is another important factor in risk stratification. In the study by Tamura et al. [2] , among patients in the monotherapy group, poor response rates at either day 3 or day 7 were evident in patients with leukemia compared with nonleukemic patients (24.4% vs. 40% at day 3; P p .106; 53.3% vs. 74% at day 7; P p .036). The response rates among patients receiving dual therapy was not dependent on the presence of leukemia (48.9% vs. 42.9% at day 3; P p .558; 73.3% vs. 79.6% at day 7; P p .474). Among leukemic patients, dual therapy was associated with significantly higher response rates at both day 3 (24.4% vs. 48.9%; P p .016) and day 7 (53.3% vs. 73.3%; P p .049) compared with monotherapy [2] . These findings underscore the important role of the underlying disease, such as leukemia, as a risk factor for treatment failure in these patients. Therefore, dual therapy is recommended for leukemic patients with febrile neutropenia.
DEGREE OF FEVER AS A RISK FACTOR
In the study by Tamura et al. [2] , we defined fever as an axillary temperature of у37.5ЊC [4, 5] , whereas the IDSA guidelines defined fever as an oral temperature of у38ЊC. Hence, to assess the importance of this discrepancy, we divided patients into 2 groups: axillary temperature of у38ЊC and axillary temperature of 37.5ЊC-38ЊC. No significant difference in efficacy of either monotherapy or dual therapy was evident between these 2 groups. Among patients receiving cefepime monotherapy, the response rate at day 3 was 23% in the 37.5ЊC-38ЊC group and 36.2% in the у38ЊC group (P p 0.223). A similar trend was observed at day 7 (65.4% vs. 63.8%; P p 0.883). Among patients receiving dual therapy with cefepime and amikacin, the difference in initial temperature did not affect the response rate at day 3 (52.4% in the !38ЊC group vs. 43.8% in the у38ЊC group; P p .488) or at day 7 (data not shown). This finding may support a cutoff point of 37.5ЊC to identify febrile patients when axillary temperature is measured. Dual therapy was more effective at day 3 in febrile neutropenic patients with axillary temperatures of !38ЊC (23.1% in the monotherapy group vs. 52.4% in the dual therapy group; P p .038). No significant differences in effectiveness of therapy were noted among patients with temperatures of у38ЊC (36.2% in the monotherapy group vs. 43.8% in the dual therapy group; P p 0.352).
SEVERITY OF INFECTION
Determining the severity of infection can be objective, but it is an important risk factor in febrile neutropenic patients, as emphasized by the IDSA guidelines (table 2) . Tamura et al. [2] demonstrated that 180% of patients with mild infections became afebrile at day 7, regardless of whether they received monotherapy or dual therapy (83.3% vs. 85.4%; Pp 1). However, even with dual therapy with cefepime and amikacin, only 32% of febrile neutropenic patients with moderate to severe infection responded at day 3, and 69.8% responded at day 7. This suggests that the severity of infection should be considered a risk factor. Among patients with moderate to severe infection, there were no significant differences between monotherapy and dual therapy at day 3 (27.7% vs. 32.1%; P p .604) or at day 7 (55.4% vs. 69.8%; P p .109).
CONCLUSIONS
Given these findings, risk stratification of patients with febrile neutropenia is important to select the appropriate antibiotic regimen. Risk stratification should be based on the 2002 IDSA guidelines. Risk factors for severe infection in febrile neutropenic patients might include the severity of neutropenia, that is, neutrophil count of !500 cells/mm 3 (A-II); the duration of neutropenia, that is, !100 cells/mm 3 for 16-7 days (A-II); the underlying disease, especially leukemia (B-II); and the severity of infection (B-III) (for explanation of strengths of recommendations, see [6] ).
